Melis Selek

Ms. Melis Selek

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MCMuharrem Okan Cakir
Muharrem Okan Cakir
MSMelis Selek
Melis Selek
BKBetul Karademir-Yilmaz
Betul Karademir-Yilmaz
MOMustafa Ozdogan
Mustafa Ozdogan
GAG. Hossein Ashrafi
G. Hossein Ashrafi
Background/Objectives: Human papillomavirus (HPV) is the main causative agent of cervical cancer and contributes to a significant proportion of other anogenital and oropharyngeal malignancies. The need for better biomarkers and therapeutic approaches in HPV-associated cancers has drawn attention to exosomes, small extracellular vesicles known for their stability, biomolecule transport capabilities, and role in cell-to-cell communication. Methods: This review comprehensively evaluates recent literature on the diagnostic, prognostic, and therapeutic applications of small extracellular vesicles, particularly exosomes, in HPV-related cancers. It analyzes findings on exosomal nucleic acids, proteins, and long non-coding RNAs, as well as engineered exosome-based therapies. Results: Exosomal miRNAs (e.g., miR-204-5p, miR-99a-5p, miR-21), proteins (e.g., glycolytic enzymes, HSP90), and lncRNAs (e.g., HOTAIR, DLEU1) have emerged as promising biomarkers for disease detection and monitoring. Exosomal cargo actively participates in HPV-related tumor progression. For example, miRNAs such as miR-21 and miR-146a modulate immune cell polarization and inflammatory signaling, while lncRNAs like HOTAIR promote oncogenic transcriptional programs. Exosomal proteins including HSP90 and ANXA1 facilitate extracellular matrix remodeling and immune evasion, thereby influencing tumor growth and metastasis. In HPV-positive head and neck and cervical cancers, exosomal cargo reflects HPV status, tumor progression, and treatment response. Therapeutic studies demonstrate the utility of exosomes in vaccine delivery, immune modulation, and drug delivery systems, including the use of PROTACs. However, clinical translation faces barriers including isolation protocol standardization, biomarker validation, and scalable production. Conclusions: Exosomes hold great promise for integration into diagnostic and therapeutic workflows for HPV-related cancers. Future research should focus on resolving standardization issues, validating biomarkers in diverse cohorts, and optimizing engineered exosome platforms for targeted therapy.

31 October 2025 in Acta Microbiologica Hellenica
Verified
Journal Article
Open access
PDF file
MCMuharrem Okan Cakir
Muharrem Okan Cakir
MSMelis Selek
Melis Selek
BKBetul Karademir-Yilmaz
Betul Karademir-Yilmaz
MOMustafa Ozdogan
Mustafa Ozdogan
GAG. Hossein Ashrafi
G. Hossein Ashrafi
Genome editing technologies, including CRISPR/Cas9, TALENs, and ZFNs, offer promising approaches to disrupt HPV oncogenes E6 and E7, thereby restoring tumor-suppressor pathways. In this review, we summarize recent preclinical findings demonstrating selective apoptosis and tumor regression in HPV-positive cell and animal models, as well as early-phase clinical studies exploring local CRISPR-based therapies. We also compare the relative strengths and limitations of major editing platforms, discuss delivery strategies, and highlight their potential integration with immunotherapy and conventional treatments. While preclinical studies show encouraging efficacy (e.g., up to 60% tumor regression in xenograft models and marked reactivation of p53/pRb pathways), translation into routine practice remains limited by challenges such as efficient delivery, minimizing off-target effects, long-term safety, cost, and ethical considerations. Continued optimization of high-fidelity nucleases, tissue-specific delivery systems, and genotype-tailored guide RNAs will be essential. Genome editing therefore represents a potential future addition to the therapeutic landscape of HPV-related diseases, but substantial barriers must be addressed before clinical implementation.

2 February 2026 in DNA
Verified
Journal Article
Open access
PDF file
MCMuharrem Okan Cakir
Muharrem Okan Cakir
MSMelis Selek
Melis Selek
GKGuldide Kayhan
Guldide Kayhan
BKBetul Karademir-Yilmaz
Betul Karademir-Yilmaz
MOMustafa Ozdogan
Mustafa Ozdogan
GAG. Hossein Ashrafi
G. Hossein Ashrafi
Human papillomavirus (HPV) infection is a leading cause of cervical cancer and a significant contributor to anogenital and oropharyngeal malignancies worldwide. While the oncogenic functions of HPV oncoproteins E6 and E7 in disrupting nuclear tumor suppressor pathways are well established, their influence on mitochondrial biology has only recently emerged as a critical facet of HPV-driven carcinogenesis. This review synthesizes current evidence on the qualitative and quantitative alterations of mitochondrial DNA (mtDNA) and their functional consequences in HPV-associated cancers. We discuss how E6 and E7 modulate mitochondrial dynamics, bioenergetics, and redox balance, contributing to metabolic reprogramming, resistance to apoptosis, and adaptation to tumor microenvironmental stress. We also examine the clinical significance of mtDNA mutations, deletions, and copy number variations as potential biomarkers for diagnosis, prognosis, and therapy response. Advances in multi-omics approaches, high-throughput sequencing, and patient-derived organoid models have accelerated the exploration of mitochondria as therapeutic targets. Integrating mitochondrial profiling into HPV-related cancer research holds promise for identifying novel metabolic vulnerabilities and guiding the development of mitochondria-directed treatment strategies.

13 July 2026 in Lung Cancer
Verified
Journal Article
Closed access
ETErkan Topkan
Erkan Topkan
MSMelis Selek
Melis Selek
USUgur Selek
Ugur Selek

5 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MCMuharrem Okan Cakir
Muharrem Okan Cakir
MSMelis Selek
Melis Selek
BKBetul Karademir-Yilmaz
Betul Karademir-Yilmaz
MOMustafa Ozdogan
Mustafa Ozdogan
GAG. Hossein Ashrafi
G. Hossein Ashrafi
Genome editing technologies including CRISPR/Cas9, TALENs, and ZFNs offer a unique opportunity to eradicate HPV by directly disrupting its oncogenes E6 and E7, thereby restoring tumour‑suppressor pathways. In this review, we provide a comprehensive overview of recent advances in HPV‑targeted genome editing, summarising key preclinical findings that demonstrate tumour regression and apoptosis in HPV‑positive models, as well as the first‑in‑human clinical trials assessing safety and feasibility of local CRISPR‑based therapies. We also compare the relative strengths and limitations of each editing platform, discuss delivery strategies, and highlight their potential integration with immunotherapy and standard cancer treatments. While genome editing shows unprecedented precision and durability in targeting viral oncogenes, challenges such as efficient delivery, minimising off‑target effects, and navigating regulatory and ethical considerations remain. Continued optimisation of high‑fidelity nucleases, tissue‑specific delivery vehicles, and personalised guide design will be essential to translate these promising approaches into routine oncology practice. Genome editing thus represents a paradigm shift in HPV therapy, with the potential to transform management of both persistent infections and established cancers.

21 August 2026 in Clinics and Practice
Verified
Journal Article
Open access
PDF file
ETErkan Topkan
Erkan Topkan
Efsun SomayEfsun Somay
Efsun Somay
MSMelis Selek
Melis Selek
USUgur Selek
Ugur Selek
This narrative methodological review aims to critically assess whether current AJCC/UICC N3-defining criteria for nasopharyngeal carcinoma (NPC) represent validated biological and statistical thresholds or pragmatic staging boundaries. Specifically, it examines the evidential basis of the >6 cm nodal-size threshold, extension below the caudal border of the cricoid cartilage, and advanced radiologic extranodal extension (rENE), with emphasis on the distinction between prognostic-variable validity and threshold validity. The >6 cm criterion is a historically inherited threshold that predates contemporary MRI-based staging and may insufficiently capture the three-dimensional complexity of nodal tumor burden. Similarly, defining inferior nodal extension by the caudal border of the cricoid cartilage improves anatomical reproducibility compared with earlier lower-neck definitions, yet it remains a pragmatic imaging landmark rather than a validated biological boundary for lymphatic dissemination. By contrast, advanced rENE is more biologically informative because it reflects invasive tumor behavior; nonetheless, its staging utility depends on standardized imaging definitions, interobserver reliability, external validation, and incremental clinical utility. Emerging imaging-derived descriptors—including MRI-based nodal diameter, nodal volume, middle-neck involvement, total tumor volume, and integrated imaging–biological models—underscore the limitations of relying exclusively on single categorical thresholds. Future N3 refinement should move beyond substituting one cutoff for another by characterizing nodal descriptors in continuous, ordinal, volumetric, or severity-graded forms before adopting simplified categories. Future refinement of NPC nodal staging will likely require approaches that move beyond isolated anatomical thresholds and better account for the multidimensional nature of nodal disease, including tumor burden, spatial distribution, invasive characteristics, and biological risk.